Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Athenex to Market Five Oncology Products from Beijing Sciecure in US

publication date: Oct 26, 2016
Athenex Pharma struck a deal with Beijing Sciecure Pharma to market five of Sciecure's injectible oncology products in the US. Athenex, a New York-Chongqing pharma, is developing proprietary cancer drugs, and it forms partnerships with pharmas to offer their products to the US market The company's in-licensing strategy helps to underwrite its R&D program. Athenex will build a US sales-marketing effort for the Sciecure products, which it will use eventually for its own products. Athenex also has first rights to oral Sciecure products in the US. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital